...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

TET Systems and AMC/STW Enter into an Assignment Agreement

| Print |
Wednesday, 02 December 2009 10:00 (UTC + 1)

 

tet_logo stw_Logo amc_logo

 

 

 

 

 

 

 

Heidelberg and Amsterdam, December 2, 2009 / b3c newswire / - TET Systems Holding (TSH), a privately-held, German biotech company based in Heidelberg, the Academic Medical Center (AMC), and Technology Foundation STW announced today that they have entered into an assignment agreement.


Scientists at the AMC have previously developed a novel series of reverse transactivators with improved properties. Under the terms of the agreement, AMC and STW assign the rights to the eight patent applications covering these new Tet transactivators to TSH for commercialization.

 

“We are very pleased to sign this agreement with AMC and STW. Since TET Systems was established in 2004, all relevant IP covering the Tet Technology was in one hand and could be offered to our licensees as a package. With the acquisition of these patent applications from AMC and STW, we broadened our IP portfolio and the rights to the core Tet Technology are again unified and can now be offered to our existing licensees and new interested parties,” stated Dr. Ernst Boehnlein, CEO of TET Systems. “TET Systems has been continuously growing its number of licensees and users of the Tet Technology over the past years. From now on, interested parties can again do ‘one-stop shopping’ for the relevant Tet Technology.”


“We are excited to enter into this partnership with TET Systems Holding as it opens the way to broad use of our improved transactivators in the scientific community, but also in the biotech and pharma industry”, added Dr. Joris Heus of AMC’s Technology Transfer Office. “The existing scientific relationship between our researchers at AMC and the inventors of the Tet Technology formed the basis for the new IP generated at AMC and led to this agreement with TET Systems.”

 

 

About TET Systems - www.tetsystems.com
TET Systems Holding is a privately held company located in Heidelberg, Germany. TET Systems Holding was founded by Prof. Dr. H. Bujard and colleagues based on their invention of the Tet Technology, the most widely used method to control gene expression in higher organisms.  TET Systems Holding owns a broad patent portfolio covering the technology organized in six patent families comprising 31 granted patents and 14 patent applications.  TET Systems markets licenses to the Tet Technology through its subsidiary IP Merchandisers.  To date, more than 150 organizations have licensed the Tet Technology including academic institutions and research foundations.  The largest group of licensees are pharmaceutical and biotech companies, with 17 of the top 20 BIG Pharma (2006) being Tet Technology licensees.

 

About AMC and STW
AMC: The Academic Medical Center (AMC) is one of the foremost research institutions in the Netherlands, as well as one of its largest hospitals. Over 7000 people work here to provide integrated patient care, fundamental and clinical scientific research, and teaching. The AMC complex houses the university hospital and the faculty of medicine of the University of Amsterdam, the Netherlands Institute for Neuroscience, the medical department of the Royal Tropical Institute and the Amsterdam Institute for Global Health and Development. A number of biotech companies (some of which are AMC spin-offs) are located on the premises. This concentration of expertise makes the centre a breeding ground for fruitful scientific collaboration.
The group of Prof. Ben Berkhout is among Europe’s leading groups in the field of HIV-related research, focusing on new therapies as well as basic research, which includes the viral evolution model that led to the development of the improved Tet transactivators.
STW: Technology Foundation STW aims to realize knowledge transfer between academic research and users in general and industry in particular by financing excellent scientific research in technology and unite researchers and potential users from the start.  The foundation was founded in 1981. Nowadays the STW office has 50 fte. About 500 projectleaders and 750 temporary scientists are working on STW research. There is an active cooperation with over 600 ventures.

 


Contacts:

TET Systems Holding GmbH & Co. KG
Dr. Ernst Böhnlein     
Chief Executive Officer    
Phone: +49 (6221) 588 0400  
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 

Academic Medical Center (AMC)
Dr. Joris Heus
Technology Development Manager
Phone: +31 (20) 5667911
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 

Technology Foundation STW
Drs. Erwin Woord
Communication advisor
Phone: +31 (30) 6001 288
This e-mail address is being protected from spambots. You need JavaScript enabled to view it